Roche’s arthritis treatment quite effective for COVID-19, study finds

news“>

A ROCK TREATMENT AGAINST ARTHRITIS QUITE EFFECTIVE AGAINST COVID-19, ACCORDING TO A STUDY

ZURICH (Reuters) – Actemra, a drug from Roche originally intended for arthritis, has shown some efficacy in treating COVID-19 in a trial of 303 patients, a said one of the study’s authors on Thursday.

This anti-inflammatory, also called tocilizumab, has achieved an “important efficacy endpoint” in critically ill patients compared to patients who have not received treatments involving modulation of the immune system, according to initial data from the REMAP-CAP test.

Anthony Gordon, professor of anesthesia and intensive care at Imperial College London, however, said it was not yet known whether Actemra saved patients and / or reduced the length of their hospital stay in units. intensive care. Details on the study are expected to be released in a few weeks, but Anthony Gordon believes initial findings show that Actemra is beneficial for patients.

Other treatments such as interferon beta 1a, interleukin-1 or even Kevzara, Sanofi’s arthritis drug, are part of the REMAP-CAP study, but their results have not yet been published. .

The study also concluded that lopinavir / ritonavir, AbbVie’s AIDS treatment, was not effective against COVID-19.

(John Miller; French version Claude Chendjou, edited by Jean-Michel Bélot)

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.